Cart summary

You have no items in your shopping cart.

LDN193189

SKU: orb1307060

Description

LDN193189 is a potent and selective BMP type I receptor inhibitor, primarily targeting ALK2 and ALK3. It is widely used in research on bone disorders like fibrodysplasia ossificans progressiva, with applications in both in vitro signaling studies and in vivo animal models of heterotopic ossification.

Research Area

Cardiovascular Research, Signal Transduction, Stem Cell & Developmental Biology

Images & Validation

−
LDN193189

Key Properties

−
CAS Number1062368-24-4
MW406.48
Purity99.86% (May vary between batches)
FormulaC25H22N6
SMILESC1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12
TargetALK,TGF-beta/Smad
SolubilityDMSO:1 mg/mL (2.46 mM);H2O:Insoluble;0.01M HCL:1.67 mg/mL (4.11 mM)

Bioactivity

−
Target IC50
ALK2:5 nM (C2C12 cells)|ALK3:30 nM (C2C12 cells)|BMPR1A:30 nM
In Vivo
Treatment of Ad.Cre-injected, caALK2-expressing mice with LDN-193189 (3 mg/kg i.p. every 12 h) prevented radiographic lesions at P15 in all mice examined. At P30, LDN-193189 prevented ectopic bone in approximately two-thirds of mice and attenuated lesions in the remainder, whereas at P60 LDN-193189 prevented ectopic bone in one-third of mice and attenuated lesions in the remainder. In contrast to vehicle-treated mice, LDN-193189–treated mice appeared to preserve knee and ankle joints at P30 and P60 . Prolonged treatment of LDLR-/- mice with LDN-193189 was well-tolerated and potently inhibited development of atheroma, as well as associated vascular inflammation, osteogenic activity, and calcification . Treatment of SCID mice bearing MDA-PCa-118b tumors with LDN-193189 significantly reduced tumor growth .
Read more...
In Vitro
LDN-193189 inhibited BMP4-mediated Smad1, Smad5 and Smad8 activation (IC50: 5 nM). LDN-193189 efficiently inhibited the transcriptional activity of the BMP type I receptors ALK2 and ALK3 (IC50s: 5/30 nM), with substantially weaker effects on activin and the TGF-β type I receptors ALK4, ALK5 and ALK7 (IC50 ≥ 500 nM). LDN-193189 inhibited the induction of alkaline phosphatase activity in C2C12 cells by BMP4 even when administered 12 h after BMP stimulation . Treatment of human aortic endothelial cells with LDN-193189 abrogated the production of reactive oxygen species induced by oxidized LDL. Treatment of mice with LDN-193189 lowered LDL serum cholesterol by 35% and markedly decreased hepatosteatosis without inhibiting HMG-CoA reductase activity. Treatment with BMP2 increased, whereas LDN-193189 inhibited apolipoprotein B100 secretion in HepG2 cells .
Read more...
Cell Research
C2C12 cells were seeded into 96-well plates at 2,000 cells per well in DMEM supplemented with 2% FBS. We treated the wells in quadruplicate with BMP ligands and LDN-193189 or vehicle. We collected the cells after 6 d in culture in 50 μl Tris-buffered saline and 1% Triton X-100. We added the lysates to p-nitro-phenylphosphate reagent in 96-well plates for 1 h and then evaluated alkaline phosphatase activity (absorbance at 405 nm). We measured cell viability and quantity by Cell Titer Aqueous One (absorbance at 490 nm), using replicate wells treated identically to those used for alkaline phosphatase measurements .
Read more...
Animal Research
In the first experiment, SCID mice were implanted with MDA-PCa-118b tumors. After 7 days when tumors reached measurable sizes, mice were injected with LDN-193189 (3 mg/kg) or with vehicle intraperitoneally twice a day. Tumor sizes and body weights were measured weekly. Mice were injected with calcein at three days and one day prior to sacrifice. Blood was collected and tumors were weighed. A portion of the tumors were fixed in formaldehyde for micro-computed tomography, using EVS CT, or further decalcified for bone histomorphometric analysis, using the OsteoMeasure Analysis System, or flash frozen for RNA preparation. Osteocalcin in the mouse serum was determined by ELISA. In the second experiment, PCa-118b tumors were first digested with Accumax, and the isolated cells were plated overnight, digested by Accutase, resuspended in Matrigel in 1:1 ratio, and injected into SCID mice (1 × 10^6 cells/mouse) subcutaneously. Mice were treated with LDN-193189 five days post-injection .
Read more...

Storage & Handling

−
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
DM3189, DM-3189, DM 3189, ALK2, ALK3, LDN 193189, LDN193189, LDN-193189, inhibit, Inhibitor, Smad, Transforming growth factor beta receptors, TGF-β/Smad, TGFbeta/Smad, TGF-beta, TGF-β Receptor, TGFβ, TGFbeta, TGFb, TGF-b/Smad

Similar Products

−
  • LDN-193189 Tetrahydrochloride

    LDN-193189 Tetrahydrochloride [orb1686141]

    98.21%

    2310134-98-4

    552.33

    C25H26Cl4N6

    25 mg, 50 mg, 5 mg, 10 mg, 100 mg, 1 mg
  • LDN-193189 HCl

    LDN-193189 HCl [orb1301025]

    >99.99% (May vary between batches)

    1062368-62-0

    442.94

    C25H22N6·HCl

    2 mg, 5 mg, 25 mg, 1 mg, 1 ml x 10 mM (in DMSO), 200 mg, 50 mg, 100 mg, 10 mg
  • LDN-193189 2HCl

    LDN-193189 2HCl [orb1694659]

    99.87% (May vary between batches)

    1435934-00-1

    479.4

    C25H24Cl2N6

    5 mg, 500 mg, 1 ml x 10 mM (in DMSO), 10 mg, 25 mg, 50 mg, 100 mg
  • LDN193189

    LDN193189 [orb546252]

    >98%

    1435934-00-1

    479.4

    C25H22N6·2HCl

    25 mg, 5 mg
  • LDN193189 HCl

    LDN193189 HCl [orb3066696]

    5 mg, 25 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID
25195294 ↗

Key Properties

−
No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Find More Protocols

LDN193189 (orb1307060)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Login to review

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

2 mg
$ 90.00
5 mg
$ 110.00
10 mg
$ 130.00
25 mg
$ 190.00
50 mg
$ 280.00
100 mg
$ 400.00
200 mg
$ 570.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry
Need technical support? Find your Distributor Return and Tax Policy

Email

info@biorbyt.com

UK Office

+44 (0)1223 859353

US Office

+1 (415) 906-5211

CN Office

+86 (27)-87663101

Distributors

biorbyt.com/distributor